 |
 Video: What is a Stock Split?
|
|
|
| BioDelivery Sciences International is a pharmaceutical company focused on delivering therapies for individuals living with serious and debilitating chronic conditions. Co.'s marketed products include: BELBUCA, which is for the management of pain severe enough to require long-term opioid treatment and for which alternative treatment options are inadequate; Symproic, which is for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; ELYXYB, which is a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and ONSOLIS/BREAKYL /PAINKYL, which is for the indication of cancer pain in opioid tolerant patients. According to our BDSI split history records, BDSI has had 0 splits. | |
|
BDSI (BDSI) has 0 splits in our BDSI split history database.
Looking at the BDSI split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BDSI shares, starting with a $10,000 purchase of BDSI, presented on a split-history-adjusted basis factoring in the complete BDSI split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/24/2013 |
|
| End date: |
03/22/2022 |
|
| Start price/share: |
$5.41 |
|
| End price/share: |
$5.59 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
3.33% |
|
| Average Annual Total Return: |
0.39% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$10,336.22 |
|
| Years: |
8.50 |
|
|
|
|
|
